Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer

Shaopeng Zhang, Shaokang Yang, Mingqi Li, Hao Zhang, Yue Cao, Sen Bai, Wei Li, Baiyu Wang, Donghao Qu, Ziqian Wang, Yanxu Sun, Daguang Wang, Liuliu Yang, Hongjie ZhangMaterials 2026 · DOI

TL;DR

Researchers have developed a novel nanoparticle (ZCH) that effectively induces cuproptosis, a specific type of cell death, in colorectal cancer cells. This nanoparticle not only delivers copper ions to trigger cell death but also simultaneously disrupts cancer cell metabolism and oxidative stress, leading to a potent anti-tumor immune response and significantly inhibiting tumor growth and metastasis in preclinical models.

What Problem Does This Paper Address?

Despite advancements in immunotherapy for colorectal cancer, many patients still experience unsatisfactory treatment outcomes due to a weak anti-tumor immune response. This paper addresses the challenge of overcoming this immune deficiency by exploring a novel cell death pathway called cuproptosis. Cuproptosis, triggered by copper ions, leads to protein aggregation and cell death, and importantly, can induce immunogenic cell death (ICD), which alerts the immune system to attack cancer cells. However, cancer cells have developed resistance mechanisms, such as increased glycolysis for energy and high levels of antioxidants like glutathione (GSH), which hinder cuproptosis. Therefore, there's a critical need for strategies that can effectively induce cuproptosis and overcome these resistance mechanisms to boost anti-tumor immunity.

Methods

The core of this research lies in the development of a multifunctional nanoparticle, termed ZnO<sub>2</sub>-Cu@HA (ZCH). The synthesis involved:

  • ZnO<sub>2</sub> Nanoparticle Synthesis: Standard underwater Leidenfrost dynamic chemistry was used to create zinc peroxide (ZnO<sub>2</sub>) nanoparticles.
  • Copper Doping: A cation-exchange method was employed to incorporate copper ions (Cu<sup>2+</sup>) into the ZnO<sub>2</sub> nanoparticles, forming Cu-doped ZnO<sub>2</sub> (ZC) nanoparticles.
  • Hyaluronic Acid Functionalization: ZC nanoparticles were further functionalized with hyaluronic acid (HA) to create ZCH. HA is known to target CD44 receptors, which are overexpressed on colorectal cancer cells, facilitating targeted delivery.

The ZCH nanoparticles were characterized using various techniques, including Transmission Electron Microscopy (TEM) for morphology, X-ray Diffraction (XRD) and X-ray Photoelectron Spectroscopy (XPS) for composition and crystal structure, ICP-OES for elemental analysis, Zeta potential and FT-IR for surface properties, and fluorescence spectroscopy to assess ROS and hydroxyl radical generation.

In vitro studies involved:

  • Cellular Uptake: FITC-labeled ZCH was used to visualize uptake in CT26 colorectal cancer cells.
  • Cytotoxicity and Therapeutic Effect: CCK-8 assays and live-dead cell staining were performed to evaluate the toxicity of ZCH and its therapeutic efficacy against CT26 cells, comparing it to free copper ions and a combination therapy.
  • Mechanism Studies: Assays were conducted to measure intracellular Zn<sup>2+</sup>, lactate (LA) levels (indicating glycolysis inhibition), ATP levels, copper content, reactive oxygen species (ROS) and mitochondrial ROS (mitoROS) generation, and glutathione (GSH) levels. Western blotting was used to assess the expression of key proteins like LDHA, GAPDH, and ATP7B. Immunofluorescence imaging and western blotting were also used to detect markers of cuproptosis (DLAT oligomerization, Fe-S cluster protein levels) and immunogenic cell death (CRT, ATP, HMGB-1).
  • DC Maturation: Bone-marrow-derived dendritic cells (BMDCs) were co-incubated with cell supernatants to assess DC maturation.

In vivo studies involved:

  • Animal Model: CT26 tumor-bearing mice were used.
  • Therapeutic Efficacy: Tumor volume, body weight, and tumor inhibition were monitored after intravenous administration of ZCH, PBS, CuCl<sub>2</sub>, and CuCl<sub>2</sub>+ZH. Histological analysis (H&E staining) and DLAT staining of tumor tissues were performed.
  • Immune Response: Flow cytometry was used to analyze DC maturation in tumor-draining lymph nodes (TDLNs) and the infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in tumor tissues. Cytokine levels (IFN-γ and TNF-α) in serum were measured.
  • Immunological Memory and Metastasis Inhibition: Spleen cells were analyzed for effector and central memory T cells. A lung metastasis model was established by injecting CT26 tumor cells after in situ treatment to evaluate ZCH's ability to prevent metastasis.

Datasets

Not discussed in the paper. The study relies on in vitro cell culture experiments and in vivo animal models.

Key Insights and Ideas

  • Synergistic Multi-pronged Attack: The ZCH nanoparticle doesn't just deliver copper; it orchestrates a multi-faceted attack on cancer cells by simultaneously:
  • Inducing Cuproptosis: Delivering Cu<sup>2+</sup> to trigger this specific cell death pathway.
  • Inhibiting Glycolysis: Released Zn<sup>2+</sup> disrupts key enzymes in glycolysis, starving cancer cells of energy.
  • Disrupting Redox Homeostasis: ZCH releases H<sub>2</sub>O<sub>2</sub> and Zn<sup>2+</sup> promotes ROS production, overwhelming the cell's antioxidant defenses.
  • Overcoming Cancer's Defenses: By inhibiting glycolysis, ZCH indirectly blocks ATP7B, a pump that normally removes copper from cells, leading to a crucial accumulation of copper inside cancer cells, thus enhancing cuproptosis. It also depletes GSH, a major antioxidant that cancer cells rely on.
  • TME-Responsiveness is Key: The ZCH nanoparticle is designed to degrade in the acidic tumor microenvironment (TME), ensuring that the therapeutic agents are released specifically where they are needed, minimizing off-target effects.
  • From Cell Death to Immune Activation: The induced cuproptosis and subsequent cell death are not just about killing cancer cells; they trigger the release of damage-associated molecular patterns (DAMPs), which are crucial signals for activating a robust anti-tumor immune response, including dendritic cell maturation and T cell activation.
  • Long-Lasting Immunity: The treatment not only eliminates primary tumors but also appears to establish immunological memory, suggesting potential for preventing recurrence and metastasis.

Key Results

  • Effective In Vitro Cytotoxicity: ZCH demonstrated significantly higher cytotoxicity against CT26 cells compared to free CuCl<sub>2</sub> or a combination of CuCl<sub>2</sub> and ZH, with only 8% cell survival in the ZCH group.
  • Metabolic and Oxidative Disruption: ZCH effectively inhibited glycolysis (reduced lactate levels), decreased intracellular ATP, and led to significant intracellular copper accumulation. It also robustly induced ROS and mitoROS generation while depleting intracellular GSH.
  • Cuproptosis and ICD Induction: ZCH treatment resulted in clear indicators of cuproptosis (DLAT oligomerization, reduced Fe-S cluster proteins) and increased release of DAMPs (CRT, ATP, HMGB-1), confirming the induction of ICD.
  • Enhanced Immune Cell Activity: ZCH treatment led to increased DC maturation and significantly higher infiltration of CD4<sup>+</sup> and CD8<sup>+</sup> T cells in tumors, along with elevated levels of pro-inflammatory cytokines IFN-γ and TNF-α.
  • Superior In Vivo Antitumor Efficacy: In CT26 tumor-bearing mice, ZCH treatment showed the most significant tumor growth inhibition and tumor volume reduction compared to control groups.
  • Prevention of Metastasis: ZCH treatment significantly reduced lung metastasis nodules and improved survival in a metastasis model.
  • Immunological Memory: ZCH treatment led to a notable increase in effector and central memory T cells, suggesting the establishment of long-term immune protection.

Limitations and Future Work

  • Limitations: While the study demonstrates promising results, it is primarily preclinical. The long-term systemic toxicity of ZCH in humans is not yet established, although initial in vivo studies showed negligible toxicity in mice. The precise mechanisms of Zn<sup>2+</sup>-mediated glycolysis inhibition and ROS generation could be further elucidated.
  • Future Work: The authors suggest that ZCH represents a promising nanoplatform for colorectal cancer immunotherapy. Future work would likely involve further optimization of the nanoparticle design, comprehensive preclinical toxicology studies, and ultimately, clinical trials to assess its efficacy and safety in human patients. The potential for combining ZCH with other cancer therapies could also be explored.

Summary updated

Abstract

Despite the immunotherapy has achieved the progress for advanced colorectal cancer, the unsatisfactory treatment effect remains a challenge due to the deficient immune response. In this work, we constructed a tumor microenvironments (TME)-responsive biodegradable cuproptosis inducer (ZnO<sub>2</sub>-Cu@HA, ZCH) through cation-exchange method for amplifying the immune response. Compared to free copper ions, ZCH cloud achieve the controllable release of Cu<sup>2+</sup> in tumor site, trggering efficient cuproptosis but reducing the side effect of normal tissues. Furthermore, the released Zn<sup>2+</sup> could also inhibit intracellular glycolysis and ATP generation, then block the ATP7B to reduce the efflux of copper ions. Meanwhile, ZCH broke intracellular redox homeostasis via the release of exogenous H<sub>2</sub>O<sub>2</sub>, Cu<sup>+</sup>-mediated Fenton-like reaction and Zn<sup>2+</sup>-induced endogenous mitoROS, amplifying the cuproptosis to inducing immunogenic cell death (ICD) triggered for highly efficient immunotherapy of colorectal cancer. These findings demonstrated that it is a promising strategy of inducing efficient cuproptosis by the synergistic effect of accumulation of copper ions, inhibiting glycolysis and down-regulation GSH for efficient immunotherapy of colorectal cancer.
BibTeX
@inproceedings{zhang2026copper,
  author = {Shaopeng Zhang and Shaokang Yang and Mingqi Li and Hao Zhang and Hao Zhang and Yue Cao and Sen Bai and Wei Li and Baiyu Wang and Donghao Qu and Ziqian Wang and W. M. Li and Yanxu Sun and Daguang Wang and Liuliu Yang and Hongjie Zhang and Hongjie Zhang},
  title = {{Copper-enriched zinc peroxides induced cuproptosis through concurrent metabolic and oxidative dysregulation for boosting immunotherapy in colorectal cancer}},
  booktitle = {Materials},
  year = {2026},
  doi = {10.1016/j.mtbio.2026.102830},
}
Figure